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Abstract
Introduction Several studies have indicated that early
identification and treatment of patients with severe sepsis using
standard supportive care improves outcomes. Earlier treatment
with drotrecogin alfa (activated) (DrotAA) may also improve
outcomes in severe sepsis. Using a recently constructed
integrated severe sepsis database, our objectives in this study
were to describe the influence of baseline clinical
characteristics on timing of DrotAA treatment in patients with
severe sepsis, to evaluate the efficacy of DrotAA with respect to
timing of administration, and to examine the association
between early intervention with DrotAA and patient outcomes,
using adjustments for imbalances.
Methods The database comprises data from 4,459 patients
with severe sepsis (DrotAA, n = 3,228; placebo, n = 1,231)
included in five clinical trials conducted in tertiary care
institutions in 28 countries. Placebo data came only from
randomized trials, whereas data for the DrotAA group came from
randomized (PROWESS) and open-label/observational
(ENHANCE) trials.
Results Increased time-to-treatment with DrotAA was
significantly associated with more organ dysfunction, greater
need of mechanical ventilation, vasopressor use, or recent
surgery. Earlier treatment was associated with higher baseline
Acute Physiology and Chronic Health Evaluation (APACHE II)
scores. Adjusted and unadjusted survival analyses suggested
that compared with placebo, DrotAA treatment provided a
potential survival benefit, regardless of time to treatment.
Survival curves of DrotAA patients treated early compared with
those treated late began to separate at 14 days. By 28 days,
patients treated earlier had higher survival than those treated
later (76.4% versus 73.5%, p = 0.03). Sepsis-induced
multiorgan dysfunction was the most common cause of death
followed by refractory shock and respiratory failure. Modeling of
the treatment effect, as a function of time to treatment,
suggested increased benefit with earlier treatment.
Conclusion Using an integrated database of five severe sepsis
trials and appropriate statistical adjustments to reduce sources
of potential bias, earlier treatment with DrotAA seemed to be
associated with a lower risk-adjusted mortality than later
treatment. These data suggest that earlier treatment with
DrotAA may provide most benefit for appropriate patients.
Introduction
Severe sepsis is a complex disease associated with high mor-
bidity and mortality. Despite improved understanding of the
pathophysiology of severe sepsis and recent advances in sup-
portive care and antimicrobial therapy, severe sepsis remainsPage 1 of 10
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APACHE = Acute Physiology and Chronic Health Evaluation; DrotAA = drotrecogin alfa (activated); ENHANCE = Extended Evaluation of Recom-
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incidence is increasing [1,2].
Among the many compounds evaluated for the treatment of
severe sepsis [3], only drotrecogin alfa (activated) (DrotAA,
also known as recombinant human activated protein C) has
been shown to reduce mortality in patients with severe sepsis.
The pivotal phase 3 placebo-controlled clinical trial PROW-
ESS (Protein C Worldwide Evaluation in Severe Sepsis) dem-
onstrated a 19.4% relative risk reduction in 28-day mortality
(6.1% absolute risk reduction) with an increased risk (3.5%
versus 2.0%) of serious bleeding events compared with pla-
cebo [4]. Subsequently, the global, open-label, single-arm
severe sepsis clinical trial ENHANCE (Extended Evaluation of
Recombinant Human Activated Protein C) showed similar
mortality rates with a somewhat higher rate of serious bleeding
events (6.5%) [5]. Recently, an integrated database, the Inter-
national Integrated Database for the Evaluation of Severe Sep-
sis and Drotrecogin alfa (activated) Therapy (INDEPTH), of
patients receiving either DrotAA or placebo enrolled in five
severe sepsis trials with similar entry criteria and conducted by
a single sponsor has been constructed and the 'integrated'
placebo and DrotAA results have been reported [6]. This large
database provides the opportunity for further analyses of pri-
mary data from a very large cohort of patients with severe
sepsis.
Recent work has shown that the early identification and treat-
ment of patients with severe sepsis using standard supportive
care significantly improves outcomes [7]. The ENHANCE trial
also suggested greater benefit in patients treated earlier (24
hours or less) than later (more than 24 hours from first docu-
mented sepsis-induced organ dysfunction (OD) to treatment)
with DrotAA [5]. Using the INDEPTH database, our objectives
in the present study were to describe the influence of baseline
clinical characteristics on the timing of treatment in patients
with severe sepsis, to evaluate the efficacy of DrotAA in
patients with severe sepsis with respect to the timing of
administration, and to examine the association between early
intervention with DrotAA and patient outcomes, using statisti-
cal modeling approaches.
Methods
The INDEPTH Database
INDEPTH combines primary data of patients with severe sep-
sis from five Eli Lilly and Company sponsored clinical trials per-
formed between July 1996 and December 2002. All trials
were reviewed and approved by the Institutional Review Board
at each participating site, and all patients or their designated
surrogate signed a written informed consent. A committee of
six experts from three countries was organized by the sponsor
to review, discuss, and provide recommendations for studies
to be included in the integrated database. After three meetings
(2003 to early 2004), five trials were identified as appropriate
for integration into the database on the committee's recom-
mendations. Ongoing trials were not and could not be consid-
ered for inclusion. Trials that ended after the creation of the
database were not included for the following reasons: the data
became available after the database had been constructed;
the patient populations were not similar enough; there was no
treatment effect; insufficient data were captured, or a mixture
of any or all of the above.
The database incorporates placebo-treated patients from four
trials: a phase II DrotAA (Xigris®; Eli Lilly and Co., Indianapolis,
IN, USA) dosing trial (performed from July 1996 to December
1997 at 40 sites in two countries) [8], the phase III PROW-
ESS trial (performed from July 1998 to June 2000 at 164 sites
in 11 countries) [4], and two trials evaluating the efficacy of a
secretory phospholipase A2 (sPLA2) inhibitor [9] (phase II, per-
formed from September 1998 to July 1999 at 72 sites in one
country, and phase IIb, performed from October 2001 to
October 2002 at 75 sites in five countries). In addition,
DrotAA-treated patients from the PROWESS and ENHANCE
trials (performed from March 2001 to December 2002 at 400
sites in 25 countries) were incorporated into the database
[4,5]. All DrotAA-treated patients in the database received
DrotAA at a dose of 24 µg kg-1 h-1 for 96 hours. Only the
PROWESS trial contributed patients who received DrotAA
and patients who received placebo (all sites and countries
contributed patients to both placebo and treatment groups).
The remaining trials either were not placebo-controlled (the
ENHANCE trial; all sites and countries contributed patients to
the treatment group), or had a treatment therapy other than
DrotAA at 24 µg kg-1 h-1 (namely the sPLA2 trials; only placebo
patients were used, and all sites and countries contributed
patients to the placebo group), or had DrotAA administered at
a variety of doses (DrotAA phase II dosing trial; only placebo
patients were used, and all sites and countries contributed
patients to the placebo group). All patients in the five trials
received supportive care at the discretion of the investigator.
Inclusion criteria were very similar across trials and, in brief,
consisted of the following: infection, presence of at least three
criteria of the systemic inflammatory response syndrome, and
at least one OD (in the phase IIb sPLA2 trial, this was at least
two ODs). Exclusion criteria in the phase II DrotAA dosing,
PROWESS, and ENHANCE trials included patients at high
risk of bleeding or likely to die from non-sepsis-related causes
within 28 days. Only patients at high risk of death from non-
sepsis-related causes within 28 days were excluded from the
sPLA2 2 trial, patients had 36 hours or less to meet inclusion
criteria, then 6 hours or less to begin study drug infusion
(patients had to have at least one OD within 24-hour period
before inclusion); for the Phase IIb/sPLA2 trial, patients had 48
hours or less to meet inclusion criteria and begin study drug
infusion (patients had to have at least three systemic inflamma-
tory response syndrome criteria within 48 hours of study drug
infusion and the presence of at least two ODs within 24 hours
from the onset of the first OD).Page 2 of 10
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Time to treatment was defined as the interval between the first
documented sepsis-induced OD and the administration of
DrotAA or placebo. Logistic regression and Cox regression
analyses were used to estimate odds and hazard ratios of 28-
day mortality associated with DrotAA versus placebo treat-
ment at increasing durations of time to treatment (continuous
data). Logistic regression analyses provided point estimates
related to a landmark endpoint at 28 days, whereas Cox
regression provided hazard ratios describing the entire sur-
vival experience over the 28-day follow-up period. These anal-
yses were adjusted for age and Acute Physiology and Chronic
Health Evaluation (APACHE) II score, as well as a propensity
score (used in observational studies to account for differences
that occur between treatment groups in non-randomized com-
parisons) to adjust for the non-randomized nature of the data.
The values of major interest in these models correspond to the
interaction between treatment and time to treatment. In addi-
tion to the above propensity score for predicting treatment
group, we also built a separate propensity for the timing of
treatment that was not included in our final models because it
did not significantly add to the value of the models. Random
effects for protocol (trial) were also considered but did not
result in statistically nonzero variances and were removed
before the final fitting of our models. Random-effects models
were constructed with Proc NLMIXED in SAS version 8.2
(SAS, Cary, NC, USA).
Table 1
Overall INDEPTH baseline patient characteristics
Parameter Placebo (n = 1,231) DrotAA (n = 3,228) p
Age, years (mean ± SD) 60.3 ± 16.5 59.5 ± 17.0 0.15a
<65 (%) 55.2 54.5 0.84b
65 – 74 (%) 24.2 25.1
≥75(%) 20.6 20.5
Male sex (%) 57.6 57.6 0.99b
Caucasian ethnicity (%) 79.4 88.3 <0.0001b
APACHE II score (mean ± SD) 24.6 ± 7.8 22.7 ± 7.5 0.0001a
<25 (%) 53.2 60.4 <0.0001b
≥25(%) 46.8 39.6
Number of ODs (mean ± SD) 2.4 ± 1.1 2.6 ± 1.1 <0.0001a
1 (%) 20.6 18.1 0.07b
≥2(%) 79.4 81.9
Time from first OD to start of infusion (mean ± SD) 23.9 ± 111.4 23.8 ± 13.6 0.97a
Mechanical ventilation (%) 78.3 79.7 0.31b
Vasopressors (%) 64.1 70.2 0.0002b
Recent surgery (%) 33.1 35.1 0.24b
APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, drotrecogin alfa (activated); INDEPTH, International Integrated Database for 
the Evaluation of Severe Sepsis and Drotrecogin alfa (activated) Therapy; OD, organ dysfunction. aStudent's t test; bχ2 test.
Figure 1
INDEPTH survival curves for placebo-receiving and DrotAA-treated patients by time to treatment
patients by time to treatment. The percentage 28-day survivals are 
shown parenthetically in the key. Kaplan-Meier survival curves are dis-
played for therapy groups (namely DrotAA and placebo), as well as for 
time-to-treatment groups (namely 0 to 24 hours and more than 24 
hours). Both DrotAA time-to-treatment curves were significantly differ-
ent from the placebo time-to-treatment curves. At 14 days, the DrotAA 
earlier treatment curve (0 to 24 hours) started to diverge from the later 
treatment curve (more than 24 hours). The difference between the 
DrotAA earlier and later treatment curves was significant at 28 days (p 
= 0.03). DrotAA, drotrecogin alfa (activated).Page 3 of 10
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an empirically defined duration for the time-to-treatment analy-
ses for purposes of simple tabular presentation. Patients were
split into two groups: those starting infusion of DrotAA or pla-
cebo within 24 hours of first documented OD (time to treat-
ment 0 to 24 hours) and those starting infusion of DrotAA or
placebo after 24 hours of first documented OD (time to treat-
ment 24 hours or more). These patients were combined
across trials for final analyses. For model building, time to treat-
ment was used as a continuous variable, to retain as much
information as possible about timing in producing model
estimates.
The univariate influence of baseline characteristics on the time
to treatment was estimated with separate linear regressions
with each baseline variable (independent variable) and time to
treat as a continuous variable (dependent variable). Joint mod-
eling on time to treatment was also performed with stepwise
selection, with alpha values of 0.05 for entry and 0.10 for
retention. Although of necessity it was assumed that all impor-
tant baseline determinants of outcome were measured, it is
understood that this is unlikely, if not impossible.
Results
There were a total of 4,459 patients in the INDEPTH database,
for 4,456 of whom 28-day mortality data were available. The
difference resulted from three patients who were discharged
from the hospital and subsequently lost to follow-up. Of the
patients with mortality data, 3,225 were patients receiving
DrotAA and 1,231 were patients receiving placebo.
Baseline characteristics of patients from the INDEPTH data-
base are presented in Table 1 and overall were relatively well
balanced. DrotAA patients had more ODs and need for vaso-
pressors but they also had somewhat lower APACHE II
scores. As shown in Table 2, baseline differences between
therapy groups were observed for ethnicity and APACHE II
score for both the treated early (0 to 24 hours) and late (more
than 24 hours) groups. It is likely that much of the difference in
APACHE II score was influenced by the ENHANCE trial,
which had uncharacteristically low APACHE II scores com-
pared with other measures of disease severity, and a longer
enrollment period [5]. Differences in number of ODs and vaso-
pressors were also observed for the more than 24 hours
group. Although other statistically significant differences were
observed, they may have little clinical significance.
Table 2
INDEPTH baseline patient characteristics based on time to treatment
Parameter Time to treatment (h) Between-treatment p
Placebo (n = 1,175) DrotAA (n = 3,216)
0 – 24 (n = 967) >24 (n = 208) 0 – 24 (n = 1,882) >24 (n = 1,334) 0 – 24 h >24 h
Age, years (mean ± SD) 60.2 ± 16.5 60.5 ± 16.0 58.9 ± 17.8 60.2 ± 15.7 0.05a 0.82a
<65 (%) 54.8 57.2 53.8 55.4
65 – 75 (%) 24.7 21.6 25.2 25.0
>75 (%) 20.5 21.2 21.0 16.6
Male sex (%) 56.3 62.0 55.8 60.1 0.83b 0.60b
Caucasian ethnicity (%) 80.4 76.4 87.1 90.0 <0.0001b <0.0001b
APACHE II score (mean ± SD) 24.9 ± 7.8 24.1 ± 7.9 23.4 ± 7.6 21.8 ± 7.3 <0.0001a <0.0001a
<25 (%) 52.2 53.8 57.2 64.9
≥25(%) 47.8 46.2 42.8 35.1
Number of ODs (mean ± SD) 2.4 ± 1.1 2.6 ± 1.1 2.5 ± 1.3 2.8 ± 1.1 0.26a 0.01a
1 (%) 21.2 17.8 23.0 11.3
≥2(%) 78.8 82.1 77.0 88.7
Time from first OD to start of infusion 
(mean ± SD)
15.7 ± 6.1 35.8 ± 12.4 15.1 ± 6.2 35.5 ± 7.9 0.01a 0.75a
Mechanical ventilation (%) 76.6 85.6 73.9 87.6 0.11b 0.41b
Vasopressors (%) 63.8 67.0 67.2 74.6 0.08b 0.02b
Recent surgery (%) 32.1 36.5 31.1 40.8 0.41b 0.50b
Total numbers of patients do not add up to those in Table 1 because of missing time-to-treatment data (44 had missing data, 23 had time-to-
treatment values of more than 72 hours, and 1 had a time-to-treatment value of less than 0). APACHE, Acute Physiology and Chronic Health 
Evaluation; DrotAA, drotrecogin alfa (activated); INDEPTH, International Integrated Database for the Evaluation of Severe Sepsis and Drotrecogin 
alfa (activated) Therapy; OD, organ dysfunction. Statistical comparisons are between DrotAA and placebo patients treated in 0 to 24 and more than 
24 hours: aStudent's t test; bχ2 test.Page 4 of 10
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ment was explored by using univariate analyses. As demon-
strated in Table 3, for patients with more sepsis-induced ODs,
patients on mechanical ventilation or vasopressors, or patients
with a recent surgery, time to treatment was significantly
increased. For example, patients who were receiving mechan-
ical ventilation were 'treated' 5.4 hours later than patients who
were not receiving mechanical ventilation, after their first doc-
umented sepsis-induced OD. There was a positive and direct
correlation between time to treatment and these baseline
characteristics. As the number of ODs increased, or patients
were receiving mechanical ventilation or vasopressors, or had
recent surgery (probably a result of protocol instruction to
commence or resume DrotAA infusion only 12 hours or more
after surgery), the time to treatment increased. In contrast,
patients with higher APACHE II scores (defined by quartiles)
were treated significantly earlier after their first documented
sepsis-induced OD. For APACHE II scores there was an
inverse relationship between time to treatment and this base-
line characteristic. As APACHE II scores increased, the time
to treatment decreased. Neither age nor sex had a significant
effect on time to treatment, although there may have been a
trend toward males being treated later. These potential
predictors of time to treatment were also fitted jointly in a mul-
tivariable model and produced similar p values and estimates
to those in univariate analyses. The exception was baseline
Table 3
Influence of baseline characteristics on duration of time to treatment based on univariate analyses
Patient variable Time to treatment (h) p (univariate)
Age (years) 0.15
<65 22.6 ± 12.3
65 – 74 22.3 ± 11.9
≥75 22.0 ± 11.4
Sex 0.08
Male 22.7 ± 12.1
Female 22.0 ± 11.9
APACHE II score < 0.0001
First quartile (3 – 17) 23.9 ± 13.4
Second quartile (18 – 22) 22.9 ± 12.5
Third quartile (23 – 28) 21.9 ± 11.2
Fourth quartile (29 – 53) 20.9 ± 10.7
Number of organ dysfunctions < 0.0001
1 19.0 ± 12.2
2 21.7 ± 11.8
3 23.6 ± 11.7
4 23.9 ± 11.5
5 27.0 ± 12.7
On a ventilator < 0.0001
Yes 23.5 ± 12.0
No 18.1 ± 10.9
On vasopressors < 0.0001
Yes 23.3 ± 11.7
No 20.9 ± 12.8
Recent surgery < 0.0001
Yes 24.4 ± 11.8
No 21.3 ± 12.0
Unknown 24.4 ± 13.2
Results are means ± SD. APACHE, Acute Physiology and Chronic Health Evaluation score. Statistics are based on one-way analysis of variance.Page 5 of 10
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sion of baseline ventilator use (data not shown).
Kaplan-Meier 28-day survival curves for patients receiving pla-
cebo and DrotAA by time to treatment are presented in Figure
1. Unadjusted and adjusted analyses suggested that there
was a potential survival benefit associated with DrotAA treat-
ment, compared with placebo, regardless of time to treatment
(only unadjusted analysis is shown). Although the two DrotAA
curves were not significantly different during the first two
weeks, they began to diverge at 14 days. The difference
between the treated early (0 to 24 hours) and the treated late
(more than 24 hours) curves became significant by 28 days.
Patients treated earlier with DrotAA (0 to 24 hours) had a sig-
nificantly higher 28-day survival (76.4%) than patients treated
later with DrotAA (more than 24 hours; 73.5%) at day 28. No
significant timing-related differences were observed in the pla-
cebo survival curves (0 to 24 hours, 68.1%; more than 24
hours, 67.8%).
Potential differences in the types of death that patients experi-
enced, based on whether they were treated early (0 to 24
hours) or late (more than 24 hours), were explored and are dis-
played in Table 4. Because in most cases the number of
events was small, we do not provide statistical values and
report the data from an observational perspective. The types
of death were categorized by treatment group (DrotAA versus
placebo), early (days 1 to 14) and late (days 15 to 28) deaths,
and by time to treatment (0 to 24 hours, and more than 24
hours). Deaths from sepsis-induced multiorgan dysfunction
(MOD) were most common, whether they occurred early or
late (days 1 to 14 and days 15 to 28). Deaths from refractory
shock and respiratory failure comprised most of the rest of the
deaths. Regardless of treatment group or time to treatment,
'late' refractory shock deaths were approximately half that of
'early' refractory shock deaths. In contrast, deaths from respi-
ratory failure increased with time (days 1 to 14 versus days 15
to 28) regardless of treatment group or time to treatment.
There was little, if any, difference in sepsis-induced MOD
deaths between DrotAA patients treated earlier (0 to 24 hours,
44.4%) and later (more than 24 hours, 41.9%) during the
period 1 to 14 days (see Table 4). However, there seemed to
be a considerable difference between those patients treated
earlier (34.0%) than later (50.5%) during the period 15 to 28
days. In contrast, placebo patients 'treated earlier' had fewer
sepsis-induced MOD deaths than those 'treated later' during
the period 1 to 14 days (43.6% versus 56.6%). Although there
were too few events during the period 15 to 28 days to pro-
duce a reasonable estimate, there were numerically fewer
deaths in placebo patients 'treated' later.
Lastly, modeling of the treatment effect was performed as a
function of time to treatment. Results from the 28-day land-
mark logistic regression (mortality odds ratios for DrotAA ver-
sus placebo at day 28) and Cox regression (mortality hazard
ratios for DrotAA versus placebo for the whole 28-day period)
analyses are presented in Figure 2. As indicated by the solid
line, in both analyses there was a trend toward a more benefi-
cial effect with earlier administration of DrotAA (odds and haz-
ard ratios less than 1 until about 36 hours). The most precise
estimates of the model were between 12 and 24 hours (nar-
rowest 95% confidence intervals shown as dashed lines). On
either side of this period, estimates were less precise because
smaller numbers of patients were treated beyond 24 hours,
indicated by the wider 95% confidence-interval lines. In the
adjusted model, logistic (28-day landmark) regression analysis
suggested that treatment with DrotAA within 24 hours of OD
was associated with lower odds of death (23%), compared
with treatment after 24 hours. Furthermore, adjusted Cox
regression analysis (whole 28-day period) suggested that ear-
lier treatment was also associated with a lower hazard of death
(19%) for the 28 days of follow-up.
Discussion
In this analysis of an integrated database of five clinical studies
in severe sepsis, the use of DrotAA was associated with
reduced mortality, regardless of the timing of treatment. This
suggests that therapy with DrotAA in patients with severe sep-
sis is beneficial, even after OD has been present for more than
24 hours. Data were sparse for treatment times of more than
36 hours after sepsis-induced OD, and therefore caution must
be used in making conclusions about the benefit of DrotAA at
later times. However, there seemed to be a trend toward
improved outcomes among patients treated earlier with
DrotAA. Such a trend was not observed among the compara-
tive placebo patients. These data suggest that the association
between the timing of treatment was due to earlier treatment
with DrotAA rather than to earlier identification of severe
sepsis.
Unlike most meta-analyses of clinical trials, the INDEPTH data-
base allows the review of patient-level data. This permits
greater risk adjustment to account for the non-randomized
nature of the study. In assessing an effect of the time of treat-
ment with DrotAA, a data set such as this is essential. For
example, in the PROWESS study [4], the average time from
initial OD to infusion of study drug was 17.5 hours. Only 11%
of PROWESS patients began DrotAA infusion more than 24
hours after OD, which limits the power of an analysis with only
the subjects from this trial. Therefore, pooling this trial with
other studies with similar inclusion and exclusion criteria per-
mits an examination that is not otherwise feasible.
To account for the differences between these studies, a variety
of statistical techniques were employed. A previously pub-
lished propensity score was used to adjust for the non-rand-
omized nature of the use of DrotAA [6]. In addition, a second
propensity score was used to adjust for covariates associated
with the time to treatment. Ultimately, there was a persistentPage 6 of 10
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DrotAA and outcome. With the adjusted model (adjusted for
covariates and propensity scores), logistic regression analysis
suggested that treatment within 24 hours of OD with DrotAA
was associated with 23% lower odds of death at 28 days,
compared with treatment more than 24 hours after sepsis-
induced OD. Also in the adjusted model, Cox regression sur-
vival analysis suggested that earlier treatment was associated
with a 19% lower adjusted hazard of death for the first 28 days
of follow-up. Given the data, these trends suggest an associa-
tion between earlier treatment with DrotAA and improved
outcomes.
Although this cohort provided considerable opportunities for
novel analyses, there were limitations to the study. Despite the
use of several statistical approaches to adjust for differences
between subjects in the various studies, this was not a single
randomized trial. Any adjustment was therefore limited to
measured covariates. In addition, the results might have been
skewed by the number of patients from individual studies [5]
and the relatively small number of placebo patients in compar-
ison with DrotAA-treated patients. The lack of placebo
patients might be of particular importance at later times, where
even less information was available. However, we were
encouraged by the similarities in baseline measures among
the subjects in the various studies. In addition, the mortality
rate among placebo patients was very similar across the stud-
ies. These similarities were reassuring and suggest that the
study cohort was relatively homogeneous. Although nonlinear
models were fitted to the data, they did not provide additional
insight or value and were therefore not included.
A limitation that could not be addressed by statistical methods
alone was a potential bias from differences in the natural pro-
gression of severe sepsis. Most subjects treated with DrotAA
more than 24 hours after OD came from a single study [5].
Because this study was not placebo controlled, it is likely that
those receiving therapy later were enrolled in the study
because of their failure to improve without DrotAA. Supporting
such a possibility, in the ENHANCE study, patients treated
later were more likely to require vasopressor agents (76% ver-
sus 71%) and mechanical ventilation (88% versus 75%) than
those treated within 24 hours of OD [5]. This could bias the
results toward a benefit for earlier treatment. Additionally,
those patients treated within the first 24 hours might have had
care providers more attentive to the signs of sepsis and poten-
tially more attentive care overall. However, extensive risk-
adjustment was used, including the use of propensity scores
for the probability of early treatment and treatment with
DrotAA. These statistical adjustments should reduce the
potential for bias in the results.
Through this analysis we were able to identify patient factors
associated with the time to treatment (see Table 3). The need
for mechanical ventilation or vasopressors, additional baseline
ODs, and recent surgery were independently associated with
a longer time to treatment with DrotAA. This might reflect the
fact that initial efforts to stabilize a patient (such as appropriate
antibiotic therapy or fluid resuscitation) were performed before
the use of DrotAA was initiated. It might also reflect the use of
APACHE II scores to direct therapy (see below). Although not
confirmed by prospective studies, the potential importance of
the timing of drug administration observed here suggests that
efforts to incorporate the use of DrotAA into early treatment
protocols for severe sepsis might serve to hasten treatment
and improve outcome. Several efforts, such as the recently
published guidelines for the treatment of severe sepsis [10],
promote the idea of early identification and treatment of
patients with severe sepsis in accordance with evidence-
based guidelines.
Table 4
Types of death by treatment, time period, and time to treatment
Type of death DrotAA Placebo
Days 1 – 14 (n = 600) Days 15 – 28 (n = 204) Days 1 – 14 (n = 287) Days 15 – 28 (n = 84)
0 – 24 h (n = 347) >24 h (n = 253) 0 – 24 h (n = 97) >24 h (n = 107) 0 – 24 h (n = 234) >24 h (n = 53) 0 – 24 h (n = 71) >24 h (n = 13)
Sepsis-induced 
multi-organ 
dysfunction, % (n)
44.4 (154) 41.9 (106) 34.0 (33) 50.5 (54) 43.6 (102) 56.6 (30) 32.4 (23) 23.1 (3)
Refractory septic 
shock, % (n)
27.1 (94) 25.3 (64) 12.4 (12) 13.1 (14) 26.1 (61) 20.8 (11) 12.7 (9) 15.4 (2)
Respiratory failure, 
% (n)
8.7 (30) 10.7 (27) 22.7 (22) 16.8 (18) 13.7 (32) 13.2 (7) 18.3 (13) 15.4 (2)
MI or primary cardiac 
arrhythmia, % (n)
5.8 (20) 6.7 (17) 10.3 (10) 5.6 (6) 3.4 (8) 1.9 (1) 2.8 (2) 15.4 (2)
Hemorrhage, % (n) 4.0 (14) 2.4 (6) 2.1 (2) 0.9 (1) 0.4 (1) None None 15.4 (2)
Other, % (n) 10.1 (35) 13.0 (33) 18.6 (18) 13.1 (14) 6.8 (16) 3.8 (2) 29.6 (21) 15.4 (2)
Other types of death include stroke and unknown causes. DrotAA, drotrecogin alfa (activated); MI, myocardial infarction.Page 7 of 10
(page number not for citation purposes)
Critical Care    Vol 10 No 3    Vincent et al.An additional factor that might have delayed treatment among
more severely ill patients is that these studies required con-
sent for subject inclusion. Sicker patients are less likely to have
the capacity to provide informed consent. The need to locate
surrogates, inform them of the seriousness of the illness, and
obtain proxy consent may delay study entry and drug
administration.
Interestingly, whereas other measures of baseline illness
severity seemed to increase the time to treatment (namely ven-
tilator use or vasopressor use), APACHE II points shortened
the interval between OD and drug administration. APACHE II
is a more global assessment of risk, including age, chronic
health status, and acute physiology score. Of these parame-
ters, the acute physiology score may decrease with increasing
time, as a result of supportive care (namely resuscitation),
which can normalize several abnormalities (such as hypoten-
sion, metabolic acidosis, and sodium abnormalities). This high-
lights the potential weakness in using APACHE II to assess
disease severity in the context of drug administration in the
intensive care unit. The delay in treatment among patients with
recent surgical procedures probably reflects the evaluation of
the bleeding risk in the early postoperative period, with a pro-
tocol requirement that patients be more than 12 hours after
surgery for inclusion.
Using a time-to-event or survival analysis, we found that the
benefit of earlier treatment with DrotAA did not become appar-
ent until after 14 days and was not statistically significant until
28 days after study entry. The separation in survival curves
between those treated with DrotAA and those receiving pla-
cebo occurred much earlier. This suggests that the benefit of
DrotAA over placebo is apparent early. However, earlier ver-
sus later DrotAA therapy has an additional effect that was not
observed until 14 days after DrotAA treatment was started. An
explanation for this observation may reside in differences in the
causes of death in severe sepsis. Sepsis-induced MOD was
the most common cause of death throughout the 28 days of
follow-up (see Table 4). However, earlier treatment (within 24
hours of OD) with DrotAA seemed to attenuate the number of
deaths due to sepsis-induced MOD, during days 15 to 28.
This difference accounted for a majority of the difference in
overall mortality seen between the group receiving earlier
DrotAA treatment and the group receiving this therapy later.
The comparative placebo group did not have a similar associ-
ation. It is possible that early treatment with DrotAA (within 24
hours of OD) does not change the course of septic shock or
respiratory failure in isolation but has a more pronounced
effect on the resolution of ODs in the form of MOD.
This study suggests that treatment with DrotAA within 24
hours may carry a larger survival advantage for patients with
severe sepsis, compared with those treated more than 24
hours after OD. However, later treatment with DrotAA was
also associated with lower mortality when compared with
patients receiving placebo. Because of the burden of disease
and the expected increase in the number of cases of severe
sepsis, there is an emphasis on improving the early identifica-
tion of severe sepsis. Recent studies showing promise in
affecting the outcome of patients with severe sepsis involve
early intervention. In a study of early goal-directed therapy of
patients with sepsis, the study protocol was begun an average
of 1.4 hours after arrival in the emergency department [7]. The
largest study of corticosteroid supplementation in severe sep-
sis required drug administration within 8 hours of hypotension
[11]. Other evidence supports the use of medical emergency
Figure 2
Landmark logistic and Cox regression analysis of DrotAA treatment effect by time to treatment. With the use of logistic (odds ratios for DrotAA ver-
sus placebo) and Cox (hazard ratios for DrotAA versus placebo) regression analyses, modeling of the treatment effect as a function of time to treat-
ment was performed. In both analyses there was a trend (logistic regression, p = 0.06; Cox regression, p = 0.07) toward a more beneficial effect 
with earlier administration of DrotAA (solid line, ratios less than 1 until 36 hours). The most precise estimates of the model were between 12 and 24 
hours, as indicated by the narrowest 95% confidence intervals (dashed lines). Outside this range, estimates of benefit were much less precise (that 
is, wider 95% confidence intervals furthest from the solid line). DrotAA, drotrecogin alfa (activated).Page 8 of 10
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sis [12]. The finding in the present study that earlier adminis-
tration of DrotAA to appropriate patients may have greater
benefit than later therapy fits into this paradigm. As sepsis
progresses, the pathophysiologic profile may change and be
less amenable to intervention. The initial pro-inflammatory
state is replaced by a condition of relative immunosuppression
[13]. Better defining the phase of illness that a septic patient
occupies might improve our ability to tailor care for each
patient. As it becomes possible to better characterize the
stage of sepsis for an individual patient, it is still likely that early
intervention will be an effective strategy. By preventing the pro-
gression to later stages of sepsis and shortening the duration
of OD, patients will be at lower risk for iatrogenic complica-
tions and secondary nosocomial infections.
Conclusion
By combining records from several clinical studies of severe
sepsis conducted by a common sponsor, the INDEPTH data-
base permits an analysis of severe sepsis therapy with the use
of patient-level data. In this data set, earlier treatment with
DrotAA, within 24 hours of OD, was associated with lower
risk-adjusted mortality than later treatment (more than 24
hours after OD). A similar time-to-treatment effect was not
observed in patients receiving placebo. Although not con-
firmed prospectively, these data suggest that earlier treatment
with DrotAA may provide the most benefit for appropriate
patients.
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